GlassScriptPhysician profile
Patrick T Ogidan
NPI 1629367602
$4,313.10
in general payments reported to CMS, 2019-2025
34 companies · $350 in 2025
The $350 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $97.49 · 2020: $467 · 2021: $761 · 2022: $916 · 2023: $950 · 2024: $772 · 2025: $350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,072.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,072.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,050.58 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $364.95 | 2022-2025 | |
| Lilly USA, LLC | $326.30 | 2020-2025 | Mounjaro, Zepbound, Trulicity |
| Amgen INC. | $307.05 | 2019-2025 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $251.55 | 2020-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Abbvie INC. | $237.30 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $205.57 | 2020-2025 | Farxiga, Airsupra |
| Novartis Pharmaceuticals Corporation | $179.91 | 2021-2023 | |
| Esperion Therapeutics, INC. | $160.05 | 2020-2024 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $140.72 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.67 | 2020-2024 | Jardiance |
| Abbott Laboratories | $103.19 | 2020-2024 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $97.58 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $89.19 | 2021-2024 | Trulance, Xifaxan |
| Exact Sciences Corporation | $66.97 | 2023-2024 | Cologuard Collection Kit |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $66.78 | 2020-2024 | Gardasil 9, Gardasil, Capvaxive |
| Tolmar, INC. | $66.54 | 2023-2025 | Jatenzo |
| Radius Health, INC. | $51.53 | 2021-2024 | Tymlos |
| Verity Pharmaceuticals INC. | $49.33 | 2024-2025 | Tlando |
| Astellas Pharma US INC | $46.72 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $41.51 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $37.89 | 2023 | Nuzyra |
| Endo Pharmaceuticals INC. | $31.06 | 2019 | |
| Allergan, INC. | $25.64 | 2020 | |
| Boston Scientific Corporation | $25.40 | 2023 | |
| Abiomed | $22.76 | 2025 | |
| Nevro Corp. | $19.24 | 2023 | Senza |
| Evoke Pharma, INC. | $18.93 | 2024 | |
| Integra Lifesciences Corporation | $17.80 | 2020 | |
| Clarus Therapeutics INC. | $16.84 | 2021 | |
| Dexcom, INC. | $16.64 | 2021 | |
| Azurity Pharmaceuticals, INC. | $15.61 | 2023 | Edarbi |
| Corcept Therapeutics | $15.28 | 2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $14.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Ogidan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.